+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Hypertension KOL Interview - US #1

  • PDF Icon

    Newsletter

  • 13 Pages
  • March 2024
  • Region: United States
  • Citeline
  • ID: 5642904
This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1-5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Adempas, Letairis, Opsumit, Orenitram, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.